Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ATM
REST API REST API
Homo sapiens
ATM is differentially expressed in 353 experiments: 126 organism parts: bone marrow, ovary, ... (124 more);, 241 disease states: normal, prostate carcinoma, ... (239 more);, 115 cell types 373 cell lines 54 compound treatments and 87 other conditions.
Synonyms ATDC, TELO1, ATA, ATD, ATC, TEL1
Orthologs TEL1 (Saccharomyces cerevisiae)   Atm (Rattus norvegicus)   ENSCING00000000816 (Ciona intestinalis)   Atm (Mus musculus)   ATM (Gallus gallus)   atm (Danio rerio)   ATM (Bos taurus)   atm (Danio rerio)   tefu (Drosophila melanogaster)   atm (Xenopus laevis)   B3VMJ2_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term chromosome, telomeric region, reciprocal meiotic recombination, histone phosphorylation, DNA damage checkpoint, DNA binding, double-strand break repair via homologous recombination, protein binding, apoptosis, phosphotransferase activity, alcohol group as acceptor, DNA repair, cytoplasm, DNA damage response, signal transduction resulting in induction of apoptosis, peptidyl-serine phosphorylation, negative regulation of apoptosis, protein N-terminus binding, cell cycle arrest, 1-phosphatidylinositol-3-kinase activity, response to hypoxia, somitogenesis, positive regulation of apoptosis, double-strand break repair, response to ionizing radiation, ATP binding, protein dimerization activity, histone serine kinase activity, spindle, regulation of cell cycle, female gamete generation, nucleus, heart development, cell death, cytoplasmic membrane-bounded vesicle, nucleotide binding, protein serine/threonine kinase activity, binding, nucleoplasm, cell cycle checkpoint, response to DNA damage stimulus, brain development, signal transduction, neuron apoptosis, G2/M transition DNA damage checkpoint, mitotic cell cycle spindle assembly checkpoint, protein kinase activity, cellular response to gamma radiation, DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest, DNA damage induced protein phosphorylation, pre-B cell allelic exclusion, negative regulation of B cell proliferation, positive regulation of neuron apoptosis, protein complex binding, positive regulation of DNA damage response, signal transduction by p53 class mediator, DNA-dependent protein kinase activity, histone mRNA catabolic process, lipoprotein catabolic process, protein autophosphorylation, protein phosphorylation, replicative senescence, histone-serine phosphorylation
InterPro Term PIK_FAT, PIK-rel_kinase_FAT, FATC, PI3/4_kinase_cat, TAN
UniProt Accession Q13315, E9PRG7, E7EV38, E9PFP9, E9PIN0, E9PIQ5
Gene-Disease Assocation BREAST CANCER, ATAXIA-TELANGIECTASIA; AT
Search EB-eye ENSG00000149311
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, ... (36 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-18005, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823, E-GEOD-3529
HT1080
2
E-MTAB-37, E-GEOD-20089
Jurkat
2
E-GEOD-1880, E-MEXP-2197
MDA-MB-231
2
E-GEOD-5823, E-TABM-420
SW480
2
E-MEXP-1014, E-MTAB-37
U87
2
E-GEOD-20089, E-MEXP-903
367 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, E-GEOD-2822, ... (49 experiments)

Factor Value U/D Experiments
centrocyte
2
E-GEOD-15271, E-TABM-702
CD34+
2
E-TABM-145, E-AFMX-5
CD56+ NK cells
2
E-AFMX-5, E-TABM-145
CD8+ T cell
1
2
E-AFMX-5, E-TABM-145, E-MTAB-25
CD14+ monocyte
1
2
3
E-AFMX-5, E-TABM-145, E-MEXP-1600
CXCR5(hi)ICOS(hi) CD4 T cell
1
E-MEXP-750
109 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-MEXP-2280, ... (73 experiments)

Factor Value U/D Experiments
prostate carcinoma
5
E-GEOD-96, E-MEXP-2034, E-MTAB-62, E-GEOD-3868, E-GEOD-7307 ... (5 experiments)
chronic lymphocytic leukemia
3
E-MTAB-37, E-GEOD-6691, E-GEOD-2466
multiple myeloma
3
E-MTAB-62, E-GEOD-6691, E-GEOD-2113
control
1
3
E-GEOD-8121, E-GEOD-16363, E-GEOD-20602, E-GEOD-20168
myeloma
2
E-MTAB-62, E-MTAB-372
acute lymphoblastic leukemia
2
E-MTAB-62, E-GEOD-96
235 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-697, ... (35 experiments)

Factor Value U/D Experiments
none
6
11
E-GEOD-5824, E-MEXP-1958, E-MEXP-1601, E-TABM-868, E-GEOD-412, ... (17 experiments)
lipopolysaccharide
3
E-MEXP-1958, E-TABM-868, E-GEOD-3720
M-CSF
1
E-GEOD-5099
TNF
1
E-GEOD-15205
dimethyl sulfoxide
1
E-GEOD-5824
unknown
1
E-GEOD-7307
48 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
1
E-GEOD-19519
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

cd3
studied in E-GEOD-22601

cd34
studied in E-GEOD-22601

cd4
studied in E-GEOD-22601

cd8
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (12 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-GEOD-1140, E-MEXP-1251, ... (12 experiments)

Clinical treatment
studied in E-GEOD-6532, E-GEOD-21610

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-19743, E-GEOD-1614, E-GEOD-6236, E-GEOD-2666, E-GEOD-4667, ... (7 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-GEOD-7788, E-MTAB-69, E-MEXP-2280, E-TABM-147, ... (7 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Erbb2
studied in E-GEOD-21653

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-7578, E-GEOD-17385, E-GEOD-20847, ... (9 experiments)

Genotype
studied in E-TABM-1029, E-MEXP-1996, E-GEOD-17476, E-GEOD-2466, E-TABM-868, ... (16 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-7011, E-MEXP-2657, E-GEOD-20540, E-GEOD-22278, ... (17 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (43 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-12254, E-MEXP-561, E-GEOD-980, E-GEOD-17400, ... (7 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977

Karyotype
studied in E-GEOD-7214, E-GEOD-22056

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Localisation of metastases
studied in E-GEOD-22541

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246 ... (5 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-MEXP-1509, E-GEOD-1676, E-MEXP-101, E-GEOD-3697, ... (6 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-GEOD-17400, E-GEOD-18995

Sex
studied in E-GEOD-19743, E-GEOD-2466, E-GEOD-3026, E-GEOD-7307

Sirna
studied in E-GEOD-21575

Stimulation
studied in E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-3494, E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-33562, E-GEOD-16837, E-MEXP-973, E-GEOD-21909, E-GEOD-19246, ... (7 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4271, E-GEOD-3494, E-GEOD-22541, E-GEOD-4922, E-TABM-147 ... (5 experiments)

Tumor size
studied in E-GEOD-8167

Processing time: 0.383 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM